Receptor-like Protein-tyrosine Phosphatase α Specifically Inhibits Insulin-increased Prolactin Gene Expression*
- From the ‡Department of Medicine,§Department of Pharmacology, and ¶Kaplan Cancer Center, New York University Medical Center, New York, New York 10016
Abstract
A physiologically relevant response to insulin, stimulation of prolactin promoter activity in GH4 pituitary cells, was used as an assay to study the specificity of protein-tyrosine phosphatase function. Receptor-like protein-tyrosine phosphatase α (RPTPα) blocks the effect of insulin to increase prolactin gene expression but potentiates the effects of epidermal growth factor and cAMP on prolactin promoter activity. RPTPα was the only protein-tyrosine phosphatase tested that did this. Thus, the effect of RPTPα on prolactin-chloramphenicol acetyltransferase (CAT) promoter activity is specific by two criteria.
A number of potential RPTPα targets were ruled out by finding (a) that they are not affected or (b) that they are not on the pathway to insulin-increased prolactin-CAT activity. The negative effect of RPTPα on insulin activation of the prolactin promoter is not due to reduced phosphorylation or kinase activity of the insulin receptor or to reduced phosphorylation of insulin receptor substrate-1 or Shc. Inhibitor studies suggest that insulin-increased prolactin gene expression is mediated by a Ras-like GTPase but is not mitogen-activated protein kinase dependent. Experiments with inhibitors of phosphatidylinositol 3-kinase suggest that insulin-increased prolactin-CAT expression is phosphatidylinositol 3-kinase-independent. These results suggest that RPTPα may be a physiological regulator of insulin action.
Footnotes
-
↵* This work was supported by National Institutes of Health Grants DK43365 (to F. M. S.) and R29CA68365 (to J. S.) and grants from the Juvenile Diabetes Foundation International (to F. M. S.) and from Sugen Inc. (to J. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵‖ To whom correspondence should be addressed: Dept. of Medicine, TH 450, NYU Medical Center, 550 First Ave., New York, NY 10016. Tel.: 212-263-7927; Fax: 212-263-7701.
-
↵1 The abbreviations used are: CAT, chloramphenicol acetyltransferase; EGF, epidermal growth factor; MAP, mitogen-activated protein; DMEM, Dulbecco’s modified Eagle’s medium; RPTP, receptor-like protein-tyrosine phosphatase; 8-CPT-cAMP, 8-(chlorophenylthio)-3′,5′-cyclic AMP; PI 3-kinase, phosphatidylinositol 3-kinase; IRS, insulin receptor substrate; MEK, MAP kinase kinase; PTPase, protein-tyrosine phosphatase; HA, hemagglutinin; RSV, Rous sarcoma virus; Prl, prolactin.
-
↵2 J. Sap, unpublished observations.
-
- Received June 12, 1997.
- Revision received October 13, 1997.
- The American Society for Biochemistry and Molecular Biology, Inc.
